The Swiss coronary stent developer Qvanteq AG closes series B financing round of 4 million Swiss Francs to obtain clinical proof of concept and CE mark
Series B financing round
Qvanteq AG today announced the successful completion of its series B financing round of 4 million Swiss Francs which has been raised from private investors. The funds will be used to obtain clinical proof of concept in a “First-in-Man” study as well as CE market approval for Qvanteq’s own novel coronary stent device.
Qvanteq’s promising bioactive and coating-free coronary stent
Pre-clinical in vivo studies with Qvanteq’s coronary stent have shown a significant reduction of restenosis in comparison to bare metal stents (BMS) and comparable or even better results than what have been observed with drug-eluting stents (DES). In addition, the studies exhibited very fast endothelialization.
Qvanteq is therefore positioning its unique bioactive and coating-free coronary stent as a valuable alternative to DES; the observed benefits of its coronary stent potentially increase patient safety while allowing a significant reduction in Dual Anti-Platelet Treatment (DAPT) time.
Qvanteq expects a straightforward market approval process, as its groundbreaking surface technology does not involve a coating or elution of any active substance, such as the release of a drug into the patient’s blood stream. Its coating-free surface technology will additionally overcome all of the problems associated with the coating technologies which are currently being applied.